Gynaecology News and Research

RSS

C-section rates on the rise

According to a California Watch analysis, profit making hospitals across the state are performing Cesarean sections at higher rates than non-profit hospitals. The analysis compiled a database of state birthing records and showed that women were at least 17 percent more likely to have a Cesarean section at a for-profit hospital than at a non-profit or public hospital from 2005 to 2007.

12 Sep 2010

BC gynecologists initiate campaign to reduce ovarian cancer mortality

Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer.

9 Sep 2010

ARID1A gene links ovarian cancer to endometriosis

Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.

9 Sep 2010

Further evidence on adverse effects of smoking on fertility

Two new studies have shed more light on how smoking may damage fertility, and give further weight to advice that mothers and fathers-to-be should stop smoking before attempting to conceive. The research is published online in the reproductive medicine journal Human Reproduction today (Wednesday 8 September).

8 Sep 2010

Eight signs of cancer: Study

Scientists have now identified eight signs of cancer that need immediate attention. These can predict the risk of cancer with such accuracy in certain age groups that patients should be referred to a specialist straight away unless there is a good explanation that is is something else.

30 Aug 2010

TomTec Imaging Systems introduces 4D MV- Assessment software for Mitral Valve measurement

TomTec Imaging Systems GmbH today announced the introduction of its new 4D MV-Assessment 2.0 software. The 4D MV- Assessment software combines the strength of 2D with the advantages of 3D echocardiography to provide the doctor with important and partly unprecedented diagnostic information and measurements for the Mitral Valve.

26 Aug 2010

Education and screening of pregnant women recommended for prevention of Fetal Alcohol Spectrum Disorder

Featured in the August edition of the Journal of Obstetrics and Gynaecology Canada is a new consensus clinical practice guideline which recommends that screening for alcohol consumption be done periodically for all pregnant women and women of child-bearing age.

13 Aug 2010

TomTec releases new version of 2D Cardiac Performance Analysis package

TomTec launches the latest version of its 2D Cardiac Performance Analysis package as part of TomTec's Image-Arena™ multimodality imaging solution.

11 Aug 2010

MabCure's MAbs 94% accurate in identifying ovarian cancer

Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.

28 Jul 2010

Highlights on reasoning behind MRC's negative decision on funding of IVF

Thirty-two years ago today, the world's first baby was born after in vitro fertilisation. However, the work that led to the birth of Louise Brown on 25 July 1978 had to be privately funded after the UK's Medical Research Council decided in 1971 against providing the Cambridge physiologist Robert Edwards and the Oldham gynaecologist Patrick Steptoe with long-term financial support. Today, an intriguing paper published in Europe's leading reproductive medicine journal Human Reproduction reveals for the first time the reasoning behind the MRC's much-criticised decision.

26 Jul 2010

Vaginal birth after previous C-section may be a safe option say doctors

According to new practice guidelines revealed for obstetricians by the American College of Obstetricians and Gynecologists this Wednesday, a vaginal birth after a Caesarean section (VBAC) or maybe even after two C-sections can be a safe and appropriate choice.

21 Jul 2010

Rottapharm Madaus, Selvita sign drug discovery services contract

Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.

20 Jul 2010

Rubicon Genomics' PicoPlex linear WGA technology proves effective in clinical study

Rubicon Genomics today announced that its PicoPlex linear whole genome amplification technology was proven to be effective in an independent clinical study organized by the European Society for Human Reproduction and Embryology. At a press conference during its 26th Annual Meeting in Rome, ESHRE reported the success of its "groundbreaking proof of principle study" showing that a new approach incorporating PicoPlex could more accurately detect and characterize chromosomal abnormalities in human eggs.

1 Jul 2010

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

A new, effective, non-surgical treatment for uterine fibroids can help women with this condition maintain their fertility, an American scientist told the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome today (Wednesday).

30 Jun 2010

Study evaluates potential risks and benefits of moderate alcohol consumption

A discussion by renowned epidemiologist Kenneth Mukamal has recently been published in the Journal of the American Medical Association, JAMA. It provides a discussion in response to a theoretical question, - if you are a 42 year old male, should you drink alcohol ( in moderation) for your health?

30 Jun 2010

Better test to predict menopause on the horizon

With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.

28 Jun 2010

Researchers review data comparing IUDs and hormonal contraceptives

Women who have had intrauterine devices fitted as contraceptives are less likely to become pregnant than those who have hormone injections, a new review by Cochrane Researchers has found. The review, which focused on women in developing countries, also found a possible link between contraceptive method and disease progression in HIV.

19 Jun 2010

Reprogrammed killer cells prevent metastasis

A team of researchers has developed a method to produce cells that kill tumour cells in the lab and prevent tumours forming in mouse models of cancer. Although the current work is in cells and mouse, if the research transfers to human biology, the new type of cell could be a new source for cell-based anticancer therapies.

11 Jun 2010

$Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer$

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.

8 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010